Active — Not RecruitingPhase 1

A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants

France24 participantsStarted 2026-01-06

Plain-language summary

The purpose of this trial is to assess the safety, tolerability, and PK of 3 doses of GRT6019 in healthy male participants. This Phase I trial will be a multiple dose trial in healthy male participants with administration of GRT6019 in 3 cohorts. For each participant, the trial consists of a Screening Period of up to 28 days, a 4 week Treatment Period (including a 2-week clinic stay and 2 weeks in an outpatient setting), and a 5 week Follow-up Period.

Who can participate

Age range18 Years – 55 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participant must be male, 18 to 55 years of age (inclusive) at the time of signing the informed consent form and affiliated to the social security system.
✓. Participant must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
✓. Participant must sign the informed consent form before any trial-related assessments.

Exclusion criteria

✕. Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, comparator, rescue medication, or any ingredients therein, or may affect the interpretation of the results, or may render the participant at high risk from treatment complications/ participation in the study unsafe
✕. Major surgical procedure, within 3 months prior to ICF signing, or anticipation of need for a major surgical procedure during the trial
✕. Clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, or immunological disorder(s)
✕. Regularly uses any medication, including herbal remedies or over-the-counter medication within 2 weeks before screening into this trial and anticipated use during the trial
✕. Concurrent enrollment in another clinical trial, unless it is an observational (non interventional) clinical trial or during the follow-up period of an interventional trial
✕. Recent participation in another clinical trial with an IMP administered within 30 days before Day 1 or within 5 times the elimination half-life of the IMP, whichever is longer

What they're measuring

Number of participants with Adverse Events (AEs)

Timeframe: Through study completion, an average of 4 Weeks

Number of participants with Serious Adverse Events (SAEs)

Timeframe: Through study completion, an average of 4 Weeks

Number of participants with AEs leading to discontinuation

Timeframe: Through study completion, an average of 4 Weeks

Number of participants with AEs related to investigational medicinal product [IMP]

Timeframe: Through study completion, an average of 4 Weeks

Trial details

NCT IDNCT07347548

SponsorGrünenthal GmbH

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-06

View on ClinicalTrials.gov More Duchenne Muscular Dystrophy (DMD) trials

Plain-language summary

Who can participate

Age range18 Years – 55 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participant must be male, 18 to 55 years of age (inclusive) at the time of signing the informed consent form and affiliated to the social security system.
✓. Participant must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
✓. Participant must sign the informed consent form before any trial-related assessments.

Exclusion criteria

✕. Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, comparator, rescue medication, or any ingredients therein, or may affect the interpretation of the results, or may render the participant at high risk from treatment complications/ participation in the study unsafe
✕. Major surgical procedure, within 3 months prior to ICF signing, or anticipation of need for a major surgical procedure during the trial
✕. Clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, or immunological disorder(s)
✕. Regularly uses any medication, including herbal remedies or over-the-counter medication within 2 weeks before screening into this trial and anticipated use during the trial
✕. Concurrent enrollment in another clinical trial, unless it is an observational (non interventional) clinical trial or during the follow-up period of an interventional trial
✕. Recent participation in another clinical trial with an IMP administered within 30 days before Day 1 or within 5 times the elimination half-life of the IMP, whichever is longer

What they're measuring

Number of participants with Adverse Events (AEs)

Timeframe: Through study completion, an average of 4 Weeks

Number of participants with Serious Adverse Events (SAEs)

Timeframe: Through study completion, an average of 4 Weeks

Number of participants with AEs leading to discontinuation

Timeframe: Through study completion, an average of 4 Weeks

Number of participants with AEs related to investigational medicinal product [IMP]

Timeframe: Through study completion, an average of 4 Weeks